View Single Post
Evo
Evo is offline
#2
Feb3-13, 11:53 PM
Mentor
Evo's Avatar
P: 25,940
Here.

Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.
http://www.sciencedaily.com/releases...1102101623.htm

CONCLUSION: Supplementation with DHA compared with placebo did not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer disease.
http://www.ncbi.nlm.nih.gov/pubmed/21045096

A lot

http://www.ncbi.nlm.nih.gov/pubmed?i...35&retmode=ref